Abcam, ab257962, Human GBP2 knockout A549 cell lysate

Size: 1Kit
GBP2 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon6.
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon6.,
Disease:Carcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-GBP2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
GBP2 also known as Guanylate Binding Protein 2 is a member of the dynamin superfamily of large GTPases. It has an approximate mass of 67 kDa. This protein finds expression predominantly in macrophages and other immune cells. The involvement of GBP2 in cellular defense mechanisms reflects its upregulation by interferon-gamma where it takes part in immune responses against microbial and viral infections.
Biological function summary
Guanylate Binding Protein 2 participates in immune response regulation. It does not function as part of a large multiprotein complex but acts primarily as a monomer. GBP2 disrupts pathogenic molecular machinery by binding to microbial enzymes leading to their inhibition which limits pathogen survival. This mechanism ensures that GBP2 remains a significant factor in the cell's intrinsic ability to fight infections at the molecular level.
Pathways
Guanylate Binding Protein 2 plays an important role in the interferon-induced defense pathways. It participates in the immune effector pathways primarily connecting to processes like the JAK-STAT signaling pathway. Through this involvement GBP2 helps enhance the expression of a variety of immunologically relevant genes. Additionally GBP2 often interacts with other members of the GBP family including GBP1 and GBP5 to amplify immune responses and signaling cascades.
Guanylate Binding Protein 2 shows a significant connection to infectious diseases like tuberculosis and viral infections such as hepatitis C. Overexpression or dysregulation of GBP2 can influence the progression and severity of these conditions. Additionally GBP2's interaction with proteins involved in inflammatory responses such as other interferon-induced proteins highlights its influence over auto-inflammatory conditions and its potential as a biomarker for disease progression.